Patents by Inventor Takeshi Furuuchi
Takeshi Furuuchi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230331724Abstract: A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.Type: ApplicationFiled: May 18, 2023Publication date: October 19, 2023Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao ABE, Takeshi FURUUCHI, Yoshiaki SAKAMAKI, Seiichi INAMURA, Akihiro MORINAKA
-
Patent number: 11731971Abstract: A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.Type: GrantFiled: August 11, 2021Date of Patent: August 22, 2023Assignee: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao Abe, Takeshi Furuuchi, Yoshiaki Sakamaki
-
Publication number: 20220348578Abstract: A crystalline form I of a compound represented by Formula (VII-1): having characteristic peaks appearing at lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 ? in the powder X-ray diffraction pattern.Type: ApplicationFiled: July 7, 2022Publication date: November 3, 2022Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao ABE, Takeshi FURUUCHI, Yoshiaki SAKAMAKI, Nakako MITSUHASHI, Yumiko SAITO
-
Patent number: 11414417Abstract: A crystalline form I of a compound represented by Formula (VII-1): having characteristic peaks appearing at lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 ? in the powder X-ray diffraction pattern.Type: GrantFiled: February 18, 2020Date of Patent: August 16, 2022Assignee: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao Abe, Takeshi Furuuchi, Yoshiaki Sakamaki, Nakako Mitsuhashi, Yumiko Saito
-
Publication number: 20210371419Abstract: A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.Type: ApplicationFiled: August 11, 2021Publication date: December 2, 2021Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao ABE, Takeshi FURUUCHI, Yoshiaki SAKAMAKI, Seiichi INAMURA, Akihiro MORINAKA
-
Patent number: 11117896Abstract: A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.Type: GrantFiled: October 22, 2019Date of Patent: September 14, 2021Assignee: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao Abe, Takeshi Furuuchi, Yoshiaki Sakamaki, Seiichi Inamura, Akihiro Morinaka
-
Publication number: 20200181143Abstract: A crystalline form I of a compound represented by Formula (VII-1): having characteristic peaks appearing at lattice spacing (d) of 7.34, 5.66, 5.53, 5.30, 5.02, 4.66, 4.37, 4.28, 4.06, 3.68, 3.62, 3.47, 3.36, 3.30, 3.16, 3.11, 3.03, 2.99 and 2.50 ? in the powder X-ray diffraction pattern.Type: ApplicationFiled: February 18, 2020Publication date: June 11, 2020Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao ABE, Takeshi FURUUCHI, Yoshiaki SAKAMAKI, Nakako MITSUHASHI, Yumiko SAITO
-
Patent number: 10604522Abstract: A process for producing a compound of the following Formula (VII-CR): The process involving providing a compound represented by the following Formula (VI): in a case where the R3ONHC(?O) side chain in the compound of the Formula (VI) has a protecting group, removing the protecting group from the compound of the Formula (VI) with an acid, and adding an ester-based poor solvent to the resultant reaction solution to precipitate the compound of Formula (VII-CR), wherein in the compounds of the Formulas (VII-CR) and (VI), R3 is a C1-6 alkyl or a heterocycle.Type: GrantFiled: October 1, 2018Date of Patent: March 31, 2020Assignee: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao Abe, Takeshi Furuuchi, Yoshiaki Sakamaki, Nakako Mitsuhashi, Yumiko Saito
-
Publication number: 20200048253Abstract: A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.Type: ApplicationFiled: October 22, 2019Publication date: February 13, 2020Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao Abe, Takeshi Furuuchi, Yoshiaki SAKAMAKI, Seiichi Inamura, Akihiro Morinaka
-
Patent number: 10556905Abstract: A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.Type: GrantFiled: May 8, 2018Date of Patent: February 11, 2020Assignee: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao Abe, Takeshi Furuuchi, Yoshiaki Sakamaki, Seiichi Inamura, Akihiro Morinaka
-
Publication number: 20190031659Abstract: A process for producing a compound of the following Formula (VII-CR): The process involving providing a compound represented by the following Formula (VI): in a case where the R3ONHC(?O) side chain in the compound of the Formula (VI) has a protecting group, removing the protecting group from the compound of the Formula (VI) with an acid, and adding an ester-based poor solvent to the resultant reaction solution to precipitate the compound of Formula (VII-CR), wherein in the compounds of the Formulas (VII-CR) and (VI), R3 is a C1-6 alkyl or a heterocycle.Type: ApplicationFiled: October 1, 2018Publication date: January 31, 2019Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao ABE, Takeshi FURUUCHI, Yoshiaki SAKAMAKI, Nakako MITSUHASHI, Yumiko SAITO
-
Patent number: 10131665Abstract: A crystalline form of a diazabicyclooctane derivative represented by the following Formula (VII), and processes for producing the same:Type: GrantFiled: October 8, 2014Date of Patent: November 20, 2018Assignee: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao Abe, Takeshi Furuuchi, Yoshiaki Sakamaki, Nakako Mitsuhashi, Yumiko Saito
-
Publication number: 20180258089Abstract: A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.Type: ApplicationFiled: May 8, 2018Publication date: September 13, 2018Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao ABE, Takeshi FURUUCHI, Yoshiaki SAKAMAKI, Seiichi INAMURA, Akihiro MORINAKA
-
Patent number: 10023573Abstract: A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.Type: GrantFiled: May 1, 2017Date of Patent: July 17, 2018Assignee: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao Abe, Takeshi Furuuchi, Yoshiaki Sakamaki, Seiichi Inamura, Akihiro Morinaka
-
Patent number: 10000492Abstract: A process for producing a compound represented by a Formula (III), including reacting a compound of the following formula with a compound selected from the group consisting of 1-hydroxypyrrolidine-2,5-dione, 2-hydroxy-3a,4,7,7a-tetrahydro-1H-isoindol-1,3(2H)-dione, 2-hydroxyhexahydro-1H-isoindol-1,3(2H)-dione and 4-hydroxy-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione, carrying out a carbonylation to obtain a compound of the following formula removing the NH protecting group P and treating the resultant compound with a base to produce a compound represented by the following formula wherein OBn is benzyloxy and R2 is hydrogen, ClCO— or Cl3COCO—.Type: GrantFiled: June 5, 2017Date of Patent: June 19, 2018Assignee: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao Abe, Takeshi Furuuchi, Yoshiaki Sakamaki, Nakako Mitsuhashi
-
Patent number: 10000491Abstract: A process for producing a diazabicyclooctane derivative represented by Formula (IV) and intermediates thereof by carrying out the following steps: wherein P is an NH protecting group capable of being removed with acid; R1 is 2,5-dioxopyrrolidin-1-yl, 1,3-dioxo-3a,4,7,7a-tetrahydro-1H-isoindol-2(3H)-yl, 1,3-dioxohexahydro-1H-isoindol-2(3H)-yl, or 3,5-dioxo-4-azatricyclo[5.2.1.02.6]dec-8-en-4-yl; R2 is hydrogen, ClCO— or Cl3COCO—; R3 is C1-6 alkyl or heterocyclyl, or forms a 3- to 7-membered heterocyclic ring together with the —O—NH— to which it is attached; and OBn is benzyloxy.Type: GrantFiled: September 24, 2014Date of Patent: June 19, 2018Assignee: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao Abe, Takeshi Furuuchi, Yoshiaki Sakamaki, Nakako Mitsuhashi
-
Publication number: 20170283415Abstract: A process for producing a compound represented by a Formula (III), including reacting a compound of the following formula with a compound selected from the group consisting of 1-hydroxypyrrolidine-2,5-dione, 2-hydroxy-3a,4,7,7a-tetrahydro-1H-isoindol-1,3(2H)-dione, 2-hydroxyhexahydro-1H-isoindol-1,3(2H)-dione and 4-hydroxy-4-azatricyclo[5.2.1.02,6]dec-8-ene-3,5-dione, carrying out a carbonylation to obtain a compound of the following formula removing the NH protecting group P and treating the resultant compound with a base to produce a compound represented by the following formula wherein OBn is benzyloxy and R2 is hydrogen, ClCO— or Cl3COCO—.Type: ApplicationFiled: June 5, 2017Publication date: October 5, 2017Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao ABE, Takeshi FURUUCHI, Yoshiaki SAKAMAKI, Nakako MITSUHASHI
-
Publication number: 20170233393Abstract: A process for preparing a diazabicyclooctane compound represented by the following formula (I): wherein A represents RcO—; B represents NH or NC1-6 alkyl; C represents a benzyl group; Rc represents a C1-6 alkyl group; A is substituted with one substituent Fn1, wherein Fn1 represents an azetidine group; the process including: (a) silylating the compound represented by the following formula (IV-c): wherein in the formula (IV-c), OBn represents benzyloxy, and (b) carrying out an intramolecular urea formation reaction.Type: ApplicationFiled: May 1, 2017Publication date: August 17, 2017Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao ABE, Takeshi FURUUCHI, Yoshiaki SAKAMAKI, Seiichi INAMURA, Akihiro MORINAKA
-
Patent number: 9708320Abstract: A diazabicyclooctane compound, which is a beta-lactame inhibitor, represented by the following formula (I): wherein A represents Ra(Rb)N— or RcO—; B represents NH or NC1-6 alkyl; C represents benzyl, H or SO3M, wherein M represents H, an inorganic or an organic cation; Ra and Rb represent H, C1-6 alkyl or acyl; Rc represents C1-6 alkyl or a heterocyclyl; A is unsubstituted or substituted with 0 to 4 substituents Fn1, wherein Fn1 represents C1-6 alkyl, O?, or Rg-(CH2)0-3—, wherein Rg represents a heterocyclyl, phenyl, heteroaryl, acyl, RdO2S—, Re(Rf)N—, Re(Rf)NCO—, ReO—, ReOCO— or a protective group, wherein Rd represents C1-6 alkyl or MO—; Re and Rf represent H or C1-6 alkyl, and a heterocycle having at least one nitrogen atom may be formed between Ra and Rb, between Rc and B, or between Re and Rf.Type: GrantFiled: October 1, 2015Date of Patent: July 18, 2017Assignee: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao Abe, Takeshi Furuuchi, Yoshiaki Sakamaki, Seiichi Inamura, Akihiro Morinaka
-
Publication number: 20160272641Abstract: A crystalline form of a diazabicyclooctane derivative represented by the following Formula (VII), and processes for producing the same:Type: ApplicationFiled: October 8, 2014Publication date: September 22, 2016Applicant: MEIJI SEIKA PHARMA CO., LTD.Inventors: Takao ABE, Takeshi FURUUCHI, Yoshiaki SAKAMAKI, Nakako MITSUHASHI, Yumiko SAITO